MDWD LONG - TRADING IDEAMDWD micro cap coming out of a nice base - phase 3 trial results and earnings on the horizon as potential catalysts here
MDWD
Innovation Product Launch For MDWD Sparks Bullish MoveCompany Information
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
Short Interest
173.05K 06/28/19
P/E Ratio (with extraordinary items)
-150.46
Analyst Average Target: $11.00
Average Analyst Recommendation: BUY
News: MediWound Ltd. (MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, will host an analyst day on its innovative product for chronic wounds on Monday, July 22nd at 12:00pm EDT in New York City. (Source: finance.yahoo.com)
